Abpro Holdings (ABPO) Total Liabilities (2021 - 2026)
Abpro Holdings' (ABPO) quarterly Total Liabilities came in at $6.9 million in Q1 2026, up 18.36% YoY from $5.8 million in Q1 2025, and up 651.92% on a QoQ basis from $913000.0 in Q4 2025.
Abpro Holdings (ABPO) Total Liabilities (2021 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 6 years of Total Liabilities data on file, last reported at $6.9 million in Q1 2026.
- Quarterly Total Liabilities rose 18.36% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 18.36% YoY) and the FY2025 annual result came in at $913000.0, down 84.26% from the prior year.
- Total Liabilities climbed to $6.9 million in Q1 2026, from $913000.0 in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $18.6 million in Q3 2024 to a low of $913000.0 in Q4 2025.
- A 5-year average of $11.5 million and a median of $11.8 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 4420.57% — and 2025, when it slumped 84.26%.
- Tracing ABPO's Total Liabilities over 5 years: stood at $15.3 million in 2022, then advanced by 5.91% to $16.2 million in 2023, then plunged by 64.18% to $5.8 million in 2024, then tumbled by 84.26% to $913000.0 in 2025, then soared by 651.92% to $6.9 million in 2026.
- The last three Total Liabilities figures came in at $6.9 million (Q1 2026), $913000.0 (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 5.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.87 Mn |
| Dec 31, 2025 | 913,000.00 |
| Sep 30, 2025 | 5.30 Mn |
| Jun 30, 2025 | 5.73 Mn |
| Mar 31, 2025 | 5.80 Mn |
| Dec 31, 2024 | 5.80 Mn |
| Sep 30, 2024 | 18.58 Mn |
| Jun 30, 2024 | 17.81 Mn |
| Mar 31, 2024 | 17.11 Mn |
| Dec 31, 2023 | 16.19 Mn |
| Sep 30, 2023 | 16.01 Mn |
| Jun 30, 2023 | 16.89 Mn |
| Mar 31, 2023 | 13.66 Mn |
| Dec 31, 2022 | 15.29 Mn |
| Sep 30, 2022 | 11.76 Mn |
| Jun 30, 2022 | 11.17 Mn |
| Mar 31, 2022 | 10.89 Mn |
| Dec 31, 2021 | 338,165.00 |